Literature DB >> 12207783

T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma.

M Fraga1, L Sánchez-Verde, J Forteza, A García-Rivero, M A Piris.   

Abstract

AIMS: An accurate diagnosis of T-cell/histiocyte-rich large B-cell lymphoma needs to take into consideration those forms of Hodgkin's lymphoma also characterized by a predominance of small lymphocytes and histiocytes, i.e. nodular lymphocyte predominance Hodgkin's lymphoma and lymphocyte-rich classical Hodgkin's lymphoma. We have studied the clinical, phenotypic and genetic features of a series of 12 cases of T-cell/histiocyte-rich large B-cell lymphoma along with 18 cases of Hodgkin's lymphoma for comparative purposes. METHODS AND
RESULTS: Of the Hodgkin's lymphoma cases, there were 11 lymphocyte predominance type and seven classic type. T-cell/histiocyte-rich large B-cell lymphomas presented usually in advanced stages (III or IV in 11/12 cases), frequently with 'B' symptoms (6/9 cases), and followed a more aggressive course than Hodgkin's lymphoma (4/8 patients died due to the tumour in T-cell/histiocyte-rich large B-cell lymphoma versus 0/15 in Hodgkin's lymphoma). T-cell/histiocyte-rich large B-cell lymphoma cases showed diffuse effacement of the nodal architecture by a proliferation of scattered large atypical B-cells obscured by a background of small T-lymphocytes (more CD8+, TIA1+ than CD57+). Five cases showed also a prominent histiocytic component. The large B-cells expressed CD45 and often EMA (6/10 cases). On the other hand, CD 30, CD15 and latent infection by Epstein-Barr virus (EBV) were generally lacking. bc l6 and CD10 were, respectively, detected in 6/6 and 1/5 cases. Conventional polymerase chain reaction (PCR) showed monoclonal immunoglobulin heavy chain (IgH) gene rearrangements in all T-cell/histiocyte-rich large B-cell lymphomas studied (5/5), but did not detect any case with t(14;18) involving the major breakpoint region (0/4).
CONCLUSIONS: The differential diagnosis of T-cell/histiocyte-rich large B-cell lymphoma from Hodgkin's lymphoma is facilitated by the integration of different immunophenotypic, molecular and clinical findings. T-cell/histiocyte-rich large B-cell lymphoma is a monoclonal neoplasm of bc l6+ B-cells with a phenotypic profile similar to lymphocyte predominance Hodgkin's lymphoma, suggesting a germinal centre origin and a possible relation to this disease. Therefore, in order to distinguish it from lymphocyte predominance Hodgkin's lymphoma, characterization of the reactive background, IgH gene rearrangement studies by conventional PCR and clinical features are more useful. In contrast, T-cell/histiocyte-rich large B-cell lymphoma can be distinguished from classical Hodgkin's lymphoma thanks to the presence of monoclonal IgH rearrangement and the CD 30-CD15-CD45+EMA+ immunophenotypic profile of the neoplastic cells in T-cell/histiocyte-rich large B-cell lymphoma.

Entities:  

Mesh:

Year:  2002        PMID: 12207783     DOI: 10.1046/j.1365-2559.2002.01466.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  13 in total

Review 1.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

2.  The histopathologic and molecular basis for the diagnosis of histiocytic sarcoma and histiocyte-associated lymphoma of mice.

Authors:  X Hao; T N Fredrickson; S K Chattopadhyay; W Han; C-F Qi; Z Wang; J M Ward; J W Hartley; H C Morse
Journal:  Vet Pathol       Date:  2010-05       Impact factor: 2.221

3.  T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Stefania Pittaluga; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

4.  EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

Authors:  Alina Nicolae; Stefania Pittaluga; Shahed Abdullah; Seth M Steinberg; Thu Anh Pham; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Elaine S Jaffe
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 5.  T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification.

Authors:  Thomas Tousseyn; Christiane De Wolf-Peeters
Journal:  Virchows Arch       Date:  2011-11-12       Impact factor: 4.064

6.  Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.

Authors:  Stefan D Dojcinov; Girish Venkataraman; Stefania Pittaluga; Iwona Wlodarska; Jeffrey A Schrager; Mark Raffeld; Robert K Hills; Elaine S Jaffe
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

7.  Irradiated Blm-deficient mice are a highly tumor prone model for analysis of a broad spectrum of hematologic malignancies.

Authors:  Madhuri Warren; Yeun-Jun Chung; William J Howat; Hannah Harrison; Ralph McGinnis; Xingpei Hao; John McCafferty; Torgny N Fredrickson; Allan Bradley; Herbert C Morse
Journal:  Leuk Res       Date:  2009-08-25       Impact factor: 3.156

8.  T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response.

Authors:  Peter Van Loo; Thomas Tousseyn; Vera Vanhentenrijk; Daan Dierickx; Agnieszka Malecka; Isabelle Vanden Bempt; Gregor Verhoef; Jan Delabie; Peter Marynen; Patrick Matthys; Chris De Wolf-Peeters
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

9.  Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma.

Authors:  Hyung-Chul Park; Sung-Hoon Jung; Jae-Sook Ahn; Mi-Young Kim; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Case Rep Oncol       Date:  2012-08-01

10.  First case of T-cell/histiocyte-rich-large B-cell lymphoma presenting with duodenal obstruction.

Authors:  Ali Riza Köksal; Huseyin Alkim; Meltem Ergun; Salih Boga; Mehmet Bayram; Canan Alkim; Ozlem Ton Eryilmaz
Journal:  Libyan J Med       Date:  2013-12-16       Impact factor: 1.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.